mcl1-in-1

Mcl1-IN-1 is a myeloid cell factor 1 inhibitor (IC50=2.4 µM).

Mcl1-IN-11 (Compound G) is a selective Mcl-1 inhibitor with Kis of 0.06 μM and 4.2 μM for Mcl-1 and Bcl-2, respectively.

Mcl1-IN-12 has anti-tumor activity.It is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively.

hMcl-1-IN-1 (Compound 9) is an hMcl-1 inhibitor based on a His224 arylsulfonyl fluoride, displaying an IC50 value of 5.8 nM.

Mcl-1-IN-17 (Compound 25) is an orally active inhibitor of myeloid cell leukemia 1 protein (Mcl-1), with a Ki of less than 0.08 nM. It exhibits significant antiproliferative activity with GI50 values of 39 nM in H929 cells and 105 nM in A427 cells, and it inhibits apoptosis. This compound is suitable for research in hematological and solid tumors.

Mcl-1-IN-16 is an effective macrolide inhibitor of myeloid cell leukemia 1 (Mcl-1) with a Ki of less than 0.08 nM. It demonstrates over 50,000-fold selectivity for Mcl-1 compared to other anti-apoptotic Bcl-2 family members, Bcl-2 and Bcl-xL. Mcl-1-IN-16 activates caspase-3/7, thereby inducing apoptosis. In tumor xenograft mouse models derived from lung cancer, it achieves tumor regression. Mcl-1-IN-16 is useful for research on solid tumors, including non-small cell lung cancer (NSCLC).

Bcl-2/Mcl-1-IN-1 is an inhibitor of Bcl-2 (Ki: 4.53 μM) and Mcl-1 (Ki: 1.19 μM), and can be used in cancer research.

MIK665 (S-64315) is a small-molecule inhibitor and a myeloid cell leukemia sequence 1 (MCL1) inhibitor (IC50 = 1.81 nM) with high selectivity and cell permeability. Used in experimental research, this compound exhibits antitumor activity in hematologic malignancies such as acute myeloid leukemia.

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

AZD-5991 Racemate is the racemate of AZD-5991. (Rac)-AZD-5991 is a novel Mcl-1 inhibitor with IC50 <3 nM in FRET assay and induces upregulation of BCL2,BCL-XL, CMYC and MCL1 in AML cell lines.

MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective dual inhibitor of Mcl-1 and Bcl-2, with IC50 values of 4.45 μM and 3.18 μM, respectively [1].

MCL-1/BCL-2-IN-2 is a potent and selective dual inhibitor of Bcl-2 and Mcl-1.

MCL-1/BCL-2-IN-3 is a selective and potent dual inhibitor of Mcl-1 and Bcl-2, with IC50 values of 5.95 and 4.78 μM, respectively.

MCL-1/BCL-2-IN-4 is a selective and potent dual inhibitor of Mcl-1 and Bcl-2.

Mcl1-IN-4 is an Mcl1 inhibitor with an IC50 of 0.2 μM.

Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) inhibitor, exhibiting an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM.

IMB-XH1 (Mcl1-IN-2) is a myeloid cell factor 1 (Mcl-1) inhibitor.

Mcl1-IN-3 is an Mcl1 inhibitor. It has an IC50 and Ki of 0.67 and 0.13 μM, respectively.

CLZ-8 (Mcl1-IN-8) is an orally active inhibitor of Mcl-1-PUMA (p53 up-regulated mediator of apoptosis) with radioprotective properties.CLZ-8 ameliorates radiation-induced HUVEC cell damage and reduces apoptosis counts, and inhibits radiation-induced overexpression of PUMA.

A-1210477-piperazinyl is a compound that specifically targets and binds to the protein myeloid cell leukemia 1 (MCL1) [myeloid cell leukemia 1]. This compound is utilized in PROTAC technology, harnessing the ability to selectively degrade target proteins.

Mcl1-IN-26 is an effective and selective myeloid cell leukemia 1 inhibitor.

(S,R)-S63845 is the isomer of S63845 and can be used as a control compound in experiments. S63845 is a potent and selective inhibitor of myeloid cell leukemia 1 (MCL1), with a binding affinity (Kd) of 0.19 nM to human MCL1.

(R,R)-S63845 is the isomer of S63845 and serves as a control compound in experiments. S63845 is a potent and selective inhibitor of myeloid cell leukemia 1 (MCL1), binding to human MCL1 with a dissociation constant (Kd) of 0.19 nM.